Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer

Henry M. Rosevear, Andrew J. Lightfoot, Thomas S. Griffith

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Conatumumab (AMG-655), under development by Amgen Inc and Japanese licensee Takeda Bio Development Center Ltd, is a fully human IgG1 mAb that binds to the extracellular domain of death receptor 5 (DR5) for the potential intravenous treatment of cancer. In vitro and in vivo studies have demonstrated that conatumumab induces apoptosis in cell lines derived from colon and pancreatic cancers, as well as in mice bearing xenograft tumors. Preclinical studies also indicated that conatumumab enhances the antitumor activity of agents, such as irinotecan and gemcitabine. The results of phase I clinical trials have demonstrated the safety of conatumumab as a monotherapy, as well as in combination with other antibody therapies or standard chemotherapeutic regimes. In addition, anti-conatumumab antibody responses have not been observed in the trials conducted to date. At the time of publication, initial results from phase I/II trials suggest a possible therapeutic role for conatumumab in patients with tumors expressing DR5.

Original languageEnglish (US)
Pages (from-to)688-698
Number of pages11
JournalCurrent Opinion in Investigational Drugs
Issue number6
StatePublished - Jun 2010


Dive into the research topics of 'Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer'. Together they form a unique fingerprint.

Cite this